These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37337526)

  • 21. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transcutaneous Electrical Cranial-Auricular Acupoint Stimulation vs. Escitalopram for Patients With Mild-to-Moderate Depression (TECAS): Study Design for a Randomized Controlled, Non-inferiority Trial.
    Yang S; Qin Z; Yang X; Chan MY; Zhang S; Rong P; Hou X; Jin G; Xu F; Liu Y; Zhang ZJ
    Front Psychiatry; 2022; 13():829932. PubMed ID: 35619617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The use of psilocybin for treatment-resistant depression].
    Johannesdottir A; Sigurdsson E
    Laeknabladid; 2022 Sep; 108(9):403-410. PubMed ID: 36040772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcutaneous electrical cranial-auricular acupoint stimulation versus escitalopram for mild-to-moderate depression: An assessor-blinded, randomized, non-inferiority trial.
    Zhang ZJ; Zhang SY; Yang XJ; Qin ZS; Xu FQ; Jin GX; Hou XB; Liu Y; Cai JF; Xiao HB; Wong YK; Zheng Y; Shi L; Zhang JN; Zhao YY; Xiao X; Zhang LL; Jiao Y; Wang Y; He JK; Chen GB; Rong PJ
    Psychiatry Clin Neurosci; 2023 Mar; 77(3):168-177. PubMed ID: 36445151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.
    Roseman L; Nutt DJ; Carhart-Harris RL
    Front Pharmacol; 2017; 8():974. PubMed ID: 29387009
    [No Abstract]   [Full Text] [Related]  

  • 26. Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial.
    Ching THW; Grazioplene R; Bohner C; Kichuk SA; DePalmer G; D'Amico E; Eilbott J; Jankovsky A; Burke M; Hokanson J; Martins B; Witherow C; Patel P; Amoroso L; Schaer H; Pittenger C; Kelmendi B
    Front Psychiatry; 2023; 14():1178529. PubMed ID: 37181888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change.
    Zeifman RJ; Wagner AC; Monson CM; Carhart-Harris RL
    J Affect Disord; 2023 Aug; 334():100-112. PubMed ID: 37146908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
    Brown ES; Howard C; Khan DA; Carmody TJ
    Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.
    Rucker JJ; Marwood L; Ajantaival RJ; Bird C; Eriksson H; Harrison J; Lennard-Jones M; Mistry S; Saldarini F; Stansfield S; Tai SJ; Williams S; Weston N; Malievskaia E; Young AH
    J Psychopharmacol; 2022 Jan; 36(1):114-125. PubMed ID: 35090363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repetitive transcranial magnetic stimulation for the treatment of major depressive disorder: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2004; 4(7):1-98. PubMed ID: 23074457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder.
    Lepola U; Wade A; Andersen HF
    Int Clin Psychopharmacol; 2004 May; 19(3):149-55. PubMed ID: 15107657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM; Llorca PM; Despiegel N; Verpillat P
    Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.
    Goodwin GM; Aaronson ST; Alvarez O; Atli M; Bennett JC; Croal M; DeBattista C; Dunlop BW; Feifel D; Hellerstein DJ; Husain MI; Kelly JR; Lennard-Jones MR; Licht RW; Marwood L; Mistry S; Páleníček T; Redjep O; Repantis D; Schoevers RA; Septimus B; Simmons HJ; Soares JC; Somers M; Stansfield SC; Stuart JR; Tadley HH; Thiara NK; Tsai J; Wahba M; Williams S; Winzer RI; Young AH; Young MB; Zisook S; Malievskaia E
    J Affect Disord; 2023 Apr; 327():120-127. PubMed ID: 36740140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
    Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
    CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of depression screening on psychiatric outcomes in patients with acute coronary syndrome: Findings from the K-DEPACS and EsDEPACS studies.
    Kang HJ; Stewart R; Bae KY; Kim SW; Shin IS; Hong YJ; Ahn Y; Jeong MH; Yoon JS; Kim JM
    Int J Cardiol; 2015; 190():114-21. PubMed ID: 25918060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials.
    Gorman JM; Korotzer A; Su G
    CNS Spectr; 2002 Apr; 7(4 Suppl 1):40-4. PubMed ID: 15131492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response.
    Sarris J; Papakostas GI; Vitolo O; Fava M; Mischoulon D
    J Affect Disord; 2014 Aug; 164():76-81. PubMed ID: 24856557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review.
    Psiuk D; Nowak EM; Dycha N; Łopuszańska U; Kurzepa J; Samardakiewicz M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232748
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.